- Home
- IGMS vs BMEA Comparison
IGMS vs BMEA Comparison
Compare IGMS & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- BMEA
- Stock Information
- Founded
- IGMS 1993
- BMEA 2017
- Country
- IGMS United States
- BMEA United States
- Employees
- IGMS N/A
- BMEA N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- IGMS Health Care
- BMEA Health Care
- Exchange
- IGMS Nasdaq
- BMEA Nasdaq
- Market Cap
- IGMS 82.1M
- BMEA 65.8M
- IPO Year
- IGMS 2019
- BMEA 2021
- Fundamental
- Price
- IGMS $1.26
- BMEA $1.55
- Analyst Decision
- IGMS Hold
- BMEA Strong Buy
- Analyst Count
- IGMS 8
- BMEA 11
- Target Price
- IGMS $6.14
- BMEA $27.60
- AVG Volume (30 Days)
- IGMS 172.4K
- BMEA 691.4K
- Earning Date
- IGMS 05-13-2025
- BMEA 05-05-2025
- Dividend Yield
- IGMS N/A
- BMEA N/A
- EPS Growth
- IGMS N/A
- BMEA N/A
- EPS
- IGMS N/A
- BMEA N/A
- Revenue
- IGMS $2,681,000.00
- BMEA N/A
- Revenue This Year
- IGMS $124.45
- BMEA N/A
- Revenue Next Year
- IGMS $45.07
- BMEA N/A
- P/E Ratio
- IGMS N/A
- BMEA N/A
- Revenue Growth
- IGMS 27.36
- BMEA N/A
- 52 Week Low
- IGMS $0.92
- BMEA $1.29
- 52 Week High
- IGMS $22.50
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- IGMS 51.89
- BMEA 45.03
- Support Level
- IGMS $1.13
- BMEA $1.29
- Resistance Level
- IGMS $1.42
- BMEA $1.52
- Average True Range (ATR)
- IGMS 0.09
- BMEA 0.14
- MACD
- IGMS 0.01
- BMEA 0.02
- Stochastic Oscillator
- IGMS 52.94
- BMEA 48.96
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.